Company intelligence / Profile preview

Sun Pharmaceutical Industries

Ownership: Public · SUNPHARMA
Employees: ~43000
Development stage: Commercial

Overview

Fourth largest global specialty generic pharmaceutical company with $5.8B revenue, operating in >100 countries with focus on complex generics and specialty drugs across multiple therapy areas[1][2][5]

Therapeutic areas: GastroenterologyCardiovascularOphthalmologyDermatologyOncologyNeurologyInfectious Diseases
Modalities: Small molecules(Implied biologics through partnerships)(Implied complex formulations)
Industry: Biotech

Drug pipeline

21 assets

OTX-101

Approved

20 more assets in the full pipeline.

Request access →

Partnerships

Philogen S.p.A(Fibromun licensing agreement)Resonance Health Ltd(Australian clinical trials partnership)

Financials

Market cap: $7.4B
Total revenue: $22.7B

Beyond the preview

Go deeper on Sun Pharmaceutical Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sun Pharmaceutical Industries.

Explore the full profile